全文获取类型
收费全文 | 250050篇 |
免费 | 12342篇 |
国内免费 | 431篇 |
专业分类
耳鼻咽喉 | 3334篇 |
儿科学 | 7920篇 |
妇产科学 | 5253篇 |
基础医学 | 35567篇 |
口腔科学 | 6029篇 |
临床医学 | 19699篇 |
内科学 | 54480篇 |
皮肤病学 | 6548篇 |
神经病学 | 22216篇 |
特种医学 | 7777篇 |
外国民族医学 | 101篇 |
外科学 | 31783篇 |
综合类 | 1110篇 |
一般理论 | 66篇 |
预防医学 | 22849篇 |
眼科学 | 4972篇 |
药学 | 17579篇 |
中国医学 | 751篇 |
肿瘤学 | 14789篇 |
出版年
2023年 | 1344篇 |
2022年 | 914篇 |
2021年 | 3698篇 |
2020年 | 2252篇 |
2019年 | 4106篇 |
2018年 | 7771篇 |
2017年 | 5186篇 |
2016年 | 5262篇 |
2015年 | 5866篇 |
2014年 | 6140篇 |
2013年 | 9842篇 |
2012年 | 16761篇 |
2011年 | 16816篇 |
2010年 | 8464篇 |
2009年 | 6384篇 |
2008年 | 14310篇 |
2007年 | 15404篇 |
2006年 | 14197篇 |
2005年 | 14096篇 |
2004年 | 13260篇 |
2003年 | 12191篇 |
2002年 | 11472篇 |
2001年 | 6604篇 |
2000年 | 6687篇 |
1999年 | 5950篇 |
1998年 | 1069篇 |
1997年 | 885篇 |
1996年 | 841篇 |
1992年 | 3471篇 |
1991年 | 3108篇 |
1990年 | 2977篇 |
1989年 | 2737篇 |
1988年 | 2609篇 |
1987年 | 2405篇 |
1986年 | 2310篇 |
1985年 | 2124篇 |
1984年 | 1583篇 |
1983年 | 1347篇 |
1982年 | 771篇 |
1979年 | 1390篇 |
1978年 | 972篇 |
1977年 | 905篇 |
1975年 | 921篇 |
1974年 | 1132篇 |
1973年 | 1139篇 |
1972年 | 1087篇 |
1971年 | 1038篇 |
1970年 | 963篇 |
1969年 | 1042篇 |
1968年 | 905篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
62.
63.
64.
Benjamin Davido Rui Batista Aurélien Dinh Pierre de Truchis E.M. Terveer Bruce Roberts Ed J. Kuijper Silvia Caballero 《International journal of antimicrobial agents》2019,53(5):553-556
Background
Spontaneous decolonization of antibiotic-resistant bacteria (ARB) takes time: approximately 25% after 30 days for carbapenem-producing Enterobacteriaceae or extended-spectrum beta-lactamase-producing Enterobacteriaceae. Faecal microbiota transplantation (FMT) has been proposed as a new strategy to promote decolonization in order to reduce the risk of superinfection due to these ARB. This paper discusses the literature on the use of FMT for this indication, and the improvement levers available to promote its efficacy.Methods
Literature available to date concerning the use of FMT to eradicate ARB was reviewed, and the different factors that may have influenced the efficacy of decolonization were evaluated.Results
Four axes that could have played major roles in the efficacy of FMT were identified: bowel preparation before FMT; donor; dose; and thermal conditioning of faeces. The positive or negative impact of each on the outcome of FMT is discussed.Conclusion
Although FMT is very efficient for the eradication of Clostridium difficile, the same ‘recipe’ cannot be used for the eradication of ARB. Working together with expert centres may help to improve the efficacy of FMT for this indication, and enable the reduction of in-hospital isolation precautions. 相似文献65.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献66.
Cristina Andrés Paula Peremiquel-Trillas Laura Gimferrer Maria Piñana Maria Gema Codina José Ángel Rodrigo-Pendás Magda Campins-Martí María Carmen Martín Francisco Fuentes Susana Rubio Tomàs Pumarola Andrés Antón 《Vaccine》2019,37(18):2470-2476
Background
Influenza viruses (FLUV) are continuously evolving, which explain the occurrence of seasonal influenza epidemics and the need to review the vaccine strain composition annually. The aim is to describe the genetic diversity and clinical outcomes of FLUV detected at a tertiary university hospital in Barcelona (Spain) during the 2012–2016 seasons.Methods
The detection of FLUV from patients attended at the Emergency Department or admitted to the hospital was performed by either immunofluorescence or PCR-based assays. A specific real-time one-step multiplex RT-PCR was performed for influenza A (FLUAV) subtyping. The complete coding haemagglutinin domain 1 (HA1) and neuraminidase (NA) (2015–2016) protein sequences from a representative sampling were molecular characterised.Results
A total 1774 (66.1%) FLUAV and 910 (33.9%) influenza B (FLUBV) cases were laboratory-confirmed. The hospitalisation rate was different between seasons, being the highest (81.4%) during the 2014–2015 season. FLUV were genetically close to vaccine strains except to the 2014–2015, in which most characterised A(H3N2) viruses belonged to a genetic group different from the vaccine strain. During the 2015–2016 season, B/Victoria-like viruses were the most predominant, but this component was not included in the trivalent vaccine used. Mutations D222G or D222N in HA1-domain were found in 3 A(H1N1)pdm09 strains from ICU-admitted cases. Three A(H1N1)pdm09 strains carried the NA H275Y (2) and S247N (1) mutations, respectively related to resistance or decreased susceptibility to oseltamivir.Conclusions
The circulation of drifted A(H3N2) strains during the 2014–2015 season was related to the high hospitalisation rate due to the mismatch with the vaccine strains. The predominance of a FLUBV lineage not included in the trivalent influenza vaccine during the 2015–2016 season highlights the need to use a tetravalent influenza vaccine. Virological surveillance of viral variants carrying protein changes that alter tropism and susceptibility to antivirals features should be strengthened in hospital settings. 相似文献67.
Wael Hegazy-Hassan José Antonio Zepeda-Escobar Laucel Ochoa-García J.M. Eloy Contreras-Ortíz Esvieta Tenorio-Borroto Alberto Barbabosa-Pliego José Esteban Aparicio-Burgos Rigoberto Oros-Pantoja Bruno Rivas-Santiago Héctor Díaz-Albiter Nisha Jain Garg Juan Carlos Vázquez-Chagoyán 《Vaccine》2019,37(2):248-257
The efforts for the development and testing of vaccines against Trypanosoma cruzi infection have increased during the past years. We have designed a TcVac series of vaccines composed of T. cruzi derived, GPI-anchored membrane antigens. The TcVac vaccines have been shown to elicit humoral and cellular mediated immune responses and provide significant (but not complete) control of experimental infection in mice and dogs. Herein, we aimed to test two immunization protocols for the delivery of DNA-prime/DNA-boost vaccine (TcVac1) composed of TcG2 and TcG4 antigens in a BALB/c mouse model. Mice were immunized with TcVac1 through intradermal/electroporation (IDE) or intramuscular (IM) routes, challenged with T. cruzi, and evaluated during acute phase of infection. The humoral immune response was evaluated through the assessment of anti-TcG2 and anti-TcG4 IgG subtypes by using an ELISA. Cellular immune response was assessed through a lymphocyte proliferation assay. Finally, clinical and morphopathological aspects were evaluated for all experimental animals. Our results demonstrated that when comparing TcVac1 IDE delivery vs IM delivery, the former induced significantly higher level of antigen-specific antibody response (IgG2a?+?IgG2b?>?IgG1) and lymphocyte proliferation, which expanded in response to challenge infection. Histological evaluation after challenge infection showed infiltration of inflammatory cells (macrophages and lymphocytes) in the heart and skeletal tissue of all infected mice. However, the largest increase in inflammatory infiltrate was observed in TcVac1_IDE/Tc mice when compared with TcVac1_IM/Tc or non-vaccinated/infected mice. The extent of tissue inflammatory infiltrate was directly associated with the control of tissue amastigote nests in vaccinated/infected (vs. non-vaccinated/infected) mice. Our results suggest that IDE delivery improves the protective efficacy of TcVac1 vaccine against T. cruzi infection in mice when compared with IM delivery of the vaccine. 相似文献
68.
69.
Paula López-Sánchez José Portolés Leyre Martín Rodríguez Fernando Tornero Arturo José Ramos Martín-Vegue José Antonio Herrero Juan Luis Cruz Bermúdez 《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2019,39(6):653-663
Introduction and objectivesChronic kidney disease has a high prevalence and economic impact, and an increased risk of hospitalization. Although there are public regional and country registries, we have not found references to estimate the impact of renal replacement therapy (RRT) on hospital admissions.MethodsWe obtained authorization from the ethics committee and health authorities to integrate the REMER [Madrid Kidney Disease Registry] (2013-2014) and Minimum Basic Data Set (2013-2015) databases and to analyze the admissions during the first year of RRT.Results767 patients started RRT in all the hospitals of our region across all RRT modalities. More than a third of the patients start dialysis during a hospital admission. This unplanned start, more common in HD than PD, shows relevant differences in patient profile or admission characteristics.Without considering this initial episode, almost 60% of patients were admitted during their first year. The hospitalization rate was 1.2 admissions/patient, higher in HD than in TX or PD; the mean length of stay was 8.6 days.The estimated cost of admissions during the first year is €12,006/patient. Our analysis ensures the exhaustive inclusion of all episodes and accurate estimation based on the discharge form.ConclusionThe impact of RRT on hospitals has been underestimated and is very relevant when calculating the total cost of RRT. Results from other countries cannot be extrapolated due to differences in the health system and patient profile. The integration of clinical databases could open up an opportunity that needs only institutional support for its development. 相似文献
70.